Immunogenicity and Safety Study of GSK Biologicals (GSK1536489A) Trivalent Split Virion Influenza Vaccine Fluviral (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years.

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals (GSK1536489A) Trivalent Split Virion Influenza Vaccine Fluviral (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs GSK 1536489A (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 17 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 17 Aug 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top